GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indo-Bangla Pharmaceuticals Ltd (DHA:IBP) » Definitions » Operating Income

Indo-Bangla Pharmaceuticals (DHA:IBP) Operating Income : BDT Mil (TTM As of . 20)


View and export this data going back to 2018. Start your Free Trial

What is Indo-Bangla Pharmaceuticals Operating Income?

Indo-Bangla Pharmaceuticals's Operating Income for the six months ended in . 20 was BDT0.00 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Indo-Bangla Pharmaceuticals's Operating Income for the six months ended in . 20 was BDT0.00 Mil. Indo-Bangla Pharmaceuticals's Revenue for the six months ended in . 20 was BDT0.00 Mil. Therefore, Indo-Bangla Pharmaceuticals's Operating Margin % for the quarter that ended in . 20 was %.

Indo-Bangla Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Indo-Bangla Pharmaceuticals Operating Income Historical Data

The historical data trend for Indo-Bangla Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indo-Bangla Pharmaceuticals Operating Income Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Operating Income

Indo-Bangla Pharmaceuticals Semi-Annual Data
Operating Income

Indo-Bangla Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in . 20 was BDT Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals  (DHA:IBP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Indo-Bangla Pharmaceuticals's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Indo-Bangla Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Indo-Bangla Pharmaceuticals's Operating Margin % for the quarter that ended in . 20 is calculated as:

Operating Margin %=Operating Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Indo-Bangla Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Indo-Bangla Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Indo-Bangla Pharmaceuticals (DHA:IBP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indo-Bangla Pharmaceuticals Ltd (DHA:IBP) » Definitions » Operating Income
Comparable Companies
Traded in Other Exchanges
N/A
Address
Plot No. 183, 6th Floor, Block B, Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Website
http://www.indo-banglapharma.com
Indo-Bangla Pharmaceuticals Ltd is engaged in manufacturing, marketing and distribution of generic pharmaceuticals products which includes human drugs dosages form such as tablet, capsule, syrup, oral saline, suspension. The products of the company are sold in domestic market. The company has also applied for permission for production and selling of veterinary medicine.